Skip to Main Content

Welcome to the new biotech M&A conundrum: Should biotechs sell now at a depressed price or wait — and pray? — for values to recover?

Consider the cancer-focused biotech Tesaro, which is exploring a sale, according to a Friday Bloomberg report. Assuming Tesaro was acquired today at the typical 50 percent premium, the purchase price would be around $3 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.